此乃要件 請即處理 閣下如對本通函任何方面或將採取的行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券交易商、銀行經 理、律師、專業會計師或其他獨立專業顧問。 閣下如已售出或轉讓名下所有上海心瑋醫療科技股份有限公司股份，應立即將本通函交予買主或承讓人，或經 手買賣或轉讓的銀行、股票經紀或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本通函全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承 擔任何責任。 本通函僅作參考用途，並不構成收購、購買或認購證券的邀約或邀請。 （股份代號：6609） (1)建議採納2025年H股激勵計劃 (2)建議授權董事會及 其授權人士處理2025年H股激勵計劃有關事宜 及 (3)臨時股東大會通告 本封面頁所用詞彙與本通函「釋義」一節所界定者具相同涵義。 董事會函件載於本通函第6至19頁。謹訂於2025年5月26日（星期一）上午十時三十分（或於緊隨股東週年大會結束後） 假座中國上海市自由貿易試驗區臨港新片區正博路356號8幢4層思脉德廳舉行臨時股東大會的通告 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 本公司將舉行臨時股東大會以考慮及（如適用）批准（其中包括）建議採納2025年 H股激勵計劃。本公司將根據上市規則適時刊發一份載有（其中包括）2025年H 股激勵計劃詳情及主要條款的通函，連同召開臨時股東大會的通告。 採納2025年H股激勵計劃須待股東批准后方可作實。本公司股東及潛在投資者 於買賣本公司證券時務請審慎行事。 承董事會命 上海心瑋醫療科技股份有限公司 董事長 王國輝 董事會（包括獨立非執行董事）認為，採納2025年H股激勵計劃將實現上述目標， 且2025年H股激勵計劃的條款屬正常商業條款且公平合理，符合本公司及股東 ...

Core Viewpoint - The company reported a total revenue of 301 million yuan for the fiscal year 2024, representing a year-on-year growth of 16.46%, while the net profit attributable to shareholders was a loss of 13.62 million yuan, an improvement from a loss of 94.01 million yuan in the previous year [2][20]. Financial Performance - Total revenue for 2024 was 301 million yuan, up 16.46% year-on-year [2][12]. - The net profit attributable to shareholders was a loss of 13.62 million yuan, compared to a loss of 94.01 million yuan in the previous year [2][20]. - The basic earnings per share were -0.36 yuan, and the weighted average return on equity was -1.26%, an increase of 7.07 percentage points from the previous year [2][16]. Cash Flow Analysis - The net cash flow from operating activities was -3.234 million yuan, an improvement of 85.17 million yuan from -88.406 million yuan in the previous year [2][20]. - The net cash flow from financing activities was -12.383 million yuan, an increase of 9.102 million yuan year-on-year [20]. - The net cash flow from investing activities was 10.796 million yuan, compared to -125 million yuan in the previous year [20]. Asset and Liability Changes - As of the end of 2024, inventory increased by 17.17%, while cash and cash equivalents decreased by 3.16% [27]. - Accounts payable increased by 43.77%, and deferred tax liabilities surged by 793.36% [30]. - The company's current ratio was 12.42, and the quick ratio was 10.34 [33]. Market Valuation - As of April 23, 2024, the company's price-to-book ratio (TTM) was approximately 0.95 times, and the price-to-sales ratio (TTM) was about 3.62 times [2].

（ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 上海心瑋醫療科技股份有限公司 （股份代號：6609） 就臨時股東大會暫停辦理H股股份過戶登記手續 茲提述上海心瑋醫療科技股份有限公司（「本公司」）日期為2025年3月27日的公 告，內容有關（其中包括）本公司於2025年4月26日（星期六）至2025年5月26日（星 期一）（包括首尾兩天）就股東週年大會暫停辦理H股（「H股」）股份過戶登記手續。 承董事會命 本公司董事會謹此進一步宣佈，本公司擬於2025年5月26日（星期一）舉行的股 東週年大會結束后於同日召開臨時股東大會（「臨時股東大會」）。 為釐定有權 出席臨時股東大會並於會上投票的本公司H股股東名 ...

此乃要件 請即處理 閣下如對本通函或將採取的行動有任何疑問，應諮詢 閣下的股票經紀或其他註冊證券交易商、銀行經理、律師、 專業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有的上海心瑋醫療科技股份有限公司股份，應立即將本通函連同隨附代表委任表格 送交買主或承讓人或經手買賣或轉讓的銀行、持牌證券交易商或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本通函全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） (1) 2024年度董事會工作報告 (2) 2024年度監事會工作報告 (3) 2024年度利潤分配方案 (4) 2024年度經審計綜合財務報表 (5) 2024年年報 (6) 董事薪酬 (7) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容所產生或因依賴該等內 容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 2024年度股東週年大會通告 茲通告上海心瑋醫療科技股份有限公司（「本公司」）謹訂於2025年5月26日（星期一） 上午10時正假座中國上海市自由貿易試驗區臨港新片區正博路356號8幢4層思脉德廳舉 行2024年股東週年大會（「股東週年大會」），以考慮及酌情通過下列決議案。除另有界 定者外，本通告所用詞彙與本公司日期為2025年4月23日之通函所界定者具有相同涵義。 普通決議案 – 1 – 1. 審議並批准2024年度本公司董事會（「董事會」）工作報告。 2. 審議並批准2024年度本公司監事會（「監事會」）工作報告。 3. 審 ...

Financial Performance - The company achieved revenue of RMB 277.9 million in 2024, representing a year-on-year increase of 19.6% from RMB 232.3 million in 2023[9]. - Gross profit for the year was RMB 181.7 million, with a gross margin decline attributed to bulk procurement pricing and market competition[9]. - The pre-tax loss significantly narrowed to RMB 12.0 million, a decrease of 88.3% compared to RMB 102.9 million in the previous year[9]. - Revenue increased by 19.6% from RMB 232.3 million for the year ended December 31, 2023, to RMB 277.9 million for the year ended December 31, 2024, primarily due to the growth in sales of acute ischemic stroke treatment devices and hemorrhagic stroke treatment devices[33]. - Gross profit rose from RMB 163.8 million to RMB 181.7 million, while gross margin decreased from 70.5% to 65.4%, mainly due to price impacts from volume-based procurement and market competition[35]. Product Development and Innovation - The company plans to launch at least two major therapeutic devices in the next two years, including a carotid stent and a self-expanding drug stent[9]. - The company introduced two innovative techniques, CATCH and CATCH mini, for treating acute ischemic stroke, improving patient outcomes[10]. - The company has obtained 31 NMPA product registrations, with applications in over 2,500 hospitals domestically[9]. - The company has obtained CE or FDA certifications for several products and is registering over 40 products in 10 countries to expand sales channels[10]. - The company has established a distribution network covering over 2,500 hospitals across all provinces in China, excluding Hong Kong and Macau, supporting its market presence[29]. - The company has developed a comprehensive product pipeline in the neurointervention field, including solutions for acute ischemic stroke and hemorrhagic stroke treatment[178]. - The company aims to continuously launch innovative medical devices to redefine care standards and improve patient outcomes[178]. Research and Development - Research and development costs amounted to RMB 58.9 million to support a diversified pipeline of neurointerventional devices[15]. - R&D costs decreased significantly from RMB 123.8 million to RMB 58.9 million, attributed to reduced raw materials and consumables for trial production, a decrease in R&D team personnel, and lower third-party contracting costs[39]. - The company has obtained NMPA approval for multiple vascular access devices, including remote access catheters and microcatheters, enhancing its product portfolio for stroke treatment and prevention[25]. - The intracranial aneurysm embolization assist stent received NMPA approval in October 2024 and has commenced sales, indicating successful product commercialization[22]. Corporate Governance - The company has a governance report for the fiscal year ending December 31, 2024, highlighting its commitment to corporate governance practices[95]. - The board consists of three executive directors, three non-executive directors, and three independent non-executive directors, ensuring a balanced distribution of power[107]. - The company has adopted a corporate governance code to enhance management standards and protect shareholder interests[101]. - Independent non-executive directors represent one-third of the board, complying with listing rules regarding independence[110]. - The company has established a nomination policy to evaluate and determine director candidates based on relevant qualifications and experience[116]. Environmental, Social, and Governance (ESG) - The group emphasizes sustainable development by integrating ESG principles into its daily operations and management strategies[182]. - The group has established annual ESG management goals covering resource usage and health safety, with regular reviews to ensure progress[182]. - The company adheres strictly to various environmental laws and regulations, ensuring compliance with national and local environmental protection requirements[196]. - The company emphasizes green development and resource utilization efficiency, aiming for sustainable innovation initiatives[196]. - The company reported total emissions of approximately 34.5 kg of waste gas in 2024, with a density of 12.4 kg per RMB 100 million in revenue, a decrease of about 2% compared to 2023[197]. Management and Workforce - The workforce consisted of 344 full-time employees as of December 31, 2024, with competitive compensation and training programs in place to enhance employee retention[55]. - The company has a strong management team with extensive backgrounds in quality control and regulatory compliance in the medical device industry[63]. - The company is committed to training new employees on corporate culture and compliance with laws and regulations[99]. - The employee gender ratio during the reporting period was 32:68, indicating a commitment to gender diversity within the workforce[136]. Strategic Goals and Market Position - The company aims to enhance brand awareness as a comprehensive provider of neurointerventional devices and expand sales of commercialized products while pushing for the commercialization of in-development products[36]. - The company aims to become a leader in the Chinese neurointerventional medical device market[99]. - The company is exploring opportunities for mergers and acquisitions to strengthen its market position[69]. - The company plans to apply for listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board, reflecting its growth strategy and market ambitions[31].

Core Viewpoint - Shanghai Xinwei Medical Technology Co., Ltd. has achieved a significant milestone in 2024 by reaching a breakeven point, enhancing investor confidence and positioning itself for future profitability [1][2]. Financial Performance - For the year ending December 31, 2024, the company reported revenue of 277.9 million yuan, a year-on-year increase of 19.6%, and a gross profit of 181.7 million yuan, up 11% [2]. - The pre-tax loss narrowed significantly to 12 million yuan, a reduction of 88.3% compared to the previous year, indicating a clear path towards profitability [2]. - The company's cost management efforts led to a decrease in sales and management expense ratio to 49.6%, down 16.6 percentage points year-on-year [2]. Strategic Focus - The company is concentrating on two main strategies: deepening its core business in neurointervention and accelerating overseas market expansion [3]. - In the neurointervention sector, the company has shifted resources towards differentiated therapeutic devices, achieving a 45.5% sales growth in acute ischemic stroke treatment devices and over 100% growth in hemorrhagic stroke treatment devices [3][4]. - The implementation of national centralized procurement policies has facilitated the penetration of the company's products into over 2,500 hospitals, with an active implantation hospital rate exceeding 80% [3]. Overseas Expansion - The company achieved overseas revenue of 8.395 million yuan in 2024, a staggering growth of 684% year-on-year, with Taiwan and India being the primary contributors [4]. - The company has obtained CE or FDA certifications for several key products, enabling entry into international markets, and plans to register products in over 30 countries within the next two years [4][12]. R&D and Innovation - Xinwei Medical is recognized as a leader in the neurointervention medical device sector, with a comprehensive product pipeline covering prevention and treatment of various neurological conditions [6]. - The company has received approvals for 31 medical devices from NMPA, 3 from FDA, and 1 from CE, showcasing its strong R&D capabilities [6]. - Recent product launches include innovative devices that fill gaps in the domestic market, enhancing the company's competitive edge [7]. Market Trends and Future Outlook - The aging population and increasing demand for rehabilitation technologies are expected to drive growth in the neurointervention sector [7]. - The brain-computer interface industry is projected to grow significantly, with a forecasted market size of $1.98 billion in 2023, reaching over $6 billion by 2028 [8]. - The company aims for an annual revenue growth of approximately 35% and a stable profit margin of 15%-20% once sales exceed 500 million yuan [9].

Core Viewpoint - The company reported a significant increase in revenue and a substantial reduction in losses, indicating improved operational efficiency and market positioning in the neuro-interventional medical device sector [1][2]. Financial Performance - The company achieved revenue of RMB 278 million for the fiscal year ending December 31, 2024, representing a year-on-year increase of 19.6% [1]. - Research and development costs amounted to RMB 58.94 million, a decrease of 52.4% compared to the previous year [1]. - The loss attributable to the parent company was RMB 13.62 million, a reduction of 85.51% year-on-year, with a loss per share of RMB 0.36 [1]. - The pre-tax loss narrowed significantly to RMB 12 million, down 88.3% year-on-year, despite a decline in gross margin due to bulk procurement pricing and market competition [1]. Operational Efficiency - The company successfully reduced the expense ratio for sales, distribution, and administrative expenses to 49.6%, down from 66.2% in 2023, reflecting effective cost control and efficiency measures [1]. - The sales volume of acute ischemic stroke treatment devices increased by 45.5%, while revenues from hemorrhagic stroke treatment devices and other interventional devices grew by 104.2% and 109.4%, respectively [1]. Product Development and Market Expansion - The company is focused on upgrading its neuro-interventional business and differentiating its treatment devices to adapt to rapidly changing market conditions [1]. - Research and development efforts are directed towards diverse neuro-interventional treatment devices, with plans to launch at least two major devices in the next 24 months, including self-expanding drug-eluting stents and carotid stents [2]. - The company has received NMPA approval for its intracranial aneurysm embolization assist stent and flow diversion device, which have begun sales [2]. - The company has obtained CE or FDA certifications for several products in overseas markets and is currently conducting over 40 product registrations in 10 countries or regions to expand sales channels [2].

Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 董事會提名委員會工作細則 第一章 總則 第一條 為規範上海心瑋醫療科技股份有限公司（以下簡稱「公司」）董事及高級 管理人員的產生，優化董事會組成，完善公司治理結構，根據《中華人民共和 國公司法》（以下簡稱「《公司法》」）等相關法律、法規、規範性文件、《上海心瑋 醫療科技股份有限公司章程》（以下簡稱「《公司章程》」）和《香港聯合交易所有 限公司證券上市規則》（以下簡稱「《上市規則》」）及中華人民共和國香港特別行 政區其他適用的法律、法規及有關規定，公司特設立董事會提名委員會，並結 合公司實際，制定本《上海心瑋醫療科技股份有限公司董事會提名委員會工作 細則》（以下簡稱「本細則」）。 第二條 董事會提名委員會是董事會按照股東大會決議設立的專門工作機構， 主要職責是擬定公司董事（包括獨立非執行董事）、總經理及其他高級管理人 員的選任程序和標準 ...